The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are:

• Does FDG PET can predict future vascular events such as stroke recurrence, myocardial infarction or vascular death among stroke survivors?
• Does FDG PET can predict other important events such as fracture, dementia, bleeding, cancer and overall death among stroke survivors? Researchers will compare the FDG uptake in major organs - such as the amygdala, vertebrae, spleen, liver, internal carotid artery, visceral fat, and psoas muscle - between patients with and without the event of interest to determine whether FDG PET can predict the overall prognosis of stroke patients.

Participants will:

• Undergo whole-body FDG PET once their neurological status has stabilized after stroke.
• Complete questionnaires assessing stress and anxiety (PHQ-9 and PSS-10) on the same day.
• Maintain regular clinic visits for up to 24 months following the index stroke

Inclusion Criteria:

• acute ischemic stroke patients who admitted within seven days after symptom onset

Exclusion Criteria:

• Patients with unstable vital signs or neurological symptoms
• Patients with estimated glomerular filtration rate less than 30ml/min
• Patients with uncontrolled diabetes requiring persistent insulin injection
• During pregnancy or while breastfeeding
• Patients with impaired consent capacity
• Patients with diagnosed/treatment for dementia
• Patients undergoing treatment for malignant tumors or serious autoimmune diseases

Patients aged 19 years and older who were diagnosed and treated for acute cerebral infarction within 7 days and can voluntarily participate in the study.